In previous studies we have found that urinary fibrinogen-derived peptides are potential tumor markers for renal cell carcinoma. These peptides occur at low concentrations in urine.
Identification of a low-abundant tumor marker requires optimal sample preparation and a highly sensitive analyzer. In this work different chromatographic and mass spectrometric methods were compared and evaluated for tumor marker discovery. We used urine samples from patients with renal cell carcinoma and prostate cancer.
Our main targets were peptides derived from fibrinogen beta with unknown sequence that are produced by differential proteolysis. With our optimized workflow we discovered 26 fibrinogen beta derived peptides that have not been identified in urine previously.
Identifer | oai:union.ndltd.org:oulo.fi/oai:oulu.fi:nbnfioulu-201512082282 |
Date | 11 December 2015 |
Creators | Mesihää, M. (Markus) |
Publisher | University of Oulu |
Source Sets | University of Oulu |
Language | English |
Detected Language | English |
Type | info:eu-repo/semantics/masterThesis, info:eu-repo/semantics/publishedVersion |
Format | application/pdf |
Rights | info:eu-repo/semantics/openAccess, © Markus Mesihää, 2015 |
Page generated in 0.0014 seconds